Needham reiterates Buy rating on Cartesian Therapeutics, $40 price target

Needham reiterated their Buy rating on Cartesian Therapeutics's stock with a price target of $40.00.The price target implies an upside of 454.8% from the Sep 28 close of $7.21.Key takeaways from the analyst noteStrong Clinical Results: The recent Phase II program demonstrated that all 5 patients tr…